Teijin Limited (TIJ.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:16AM CEST. Market open.
| Previous close | 9.15 |
| Open | 9.05 |
| Bid | 9.10 x 170000 |
| Ask | 9.25 x 160000 |
| Day's range | 9.05 - 9.05 |
| 52-week range | 7.50 - 10.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.779B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.23 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | 0.18 (2.03%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireAscendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones – Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasd
© 2024 Yahoo. All rights reserved.